Current nanotechnological approaches for an effective delivery of bio-active drug molecules in the treatment of acne

Artificial Cells, Nanomedicine and Biotechnology

Volumn 44, Issue 1, 2016, Pages 98-105

  Garg, Tarun ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

Acne vulgaris; Fullerenes; Liposomes; Micro sponge; Propionibacterium acnes

Indexed keywords

DISEASE CONTROL; EMULSIFICATION; EMULSIONS; FULLERENES; LIPOSOMES; SKIN; TARGETED DRUG DELIVERY;

ACNE VULGARIS; CHRONIC INFLAMMATORY; COLLOIDAL DRUGS; MICRO-SPONGE; NANO-EMULSIONS; PROPIONIBACTERIUM ACNES; SOLID LIPID NANOPARTICLE (SLN); TREATMENT SYSTEMS;

CONTROLLED DRUG DELIVERY;

ADAPALENE; ANTI ACNE AGENT; ANTIBIOTIC AGENT; AZITHROMYCIN; CLARITHROMYCIN; CLINDAMYCIN; ERYTHROMYCIN; FULLERENE DERIVATIVE; HERBACEOUS AGENT; ISOTRETINOIN; LIPOSOME; METRETINIDE; MICROSPHERE; NADIFLOXACIN; NIOSOME; RETINOIC ACID; RETINOID; SOLID LIPID NANOPARTICLE; TAZAROTENE; UNCLASSIFIED DRUG; ANDROGEN; ANTIANDROGEN; ANTIINFECTIVE AGENT; EMULSION; NANOPARTICLE; PLANT MEDICINAL PRODUCT;

ACNE; DISPERSION; HUMAN; MICROEMULSION; NANOTECHNOLOGY; PATHOGENESIS; REVIEW; ACNE VULGARIS; BIOSYNTHESIS; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; EMULSION; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MICROBIOLOGY; PATHOGENICITY; PATHOLOGY; PROCEDURES; PROPIONIBACTERIUM ACNES; SEBUM; SKIN;

ACNE VULGARIS; ANDROGEN ANTAGONISTS; ANDROGENS; ANTI-BACTERIAL AGENTS; DRUG DELIVERY SYSTEMS; EMULSIONS; FULLERENES; HUMANS; LIPOSOMES; MICROSPHERES; NANOPARTICLES; PLANT PREPARATIONS; PROPIONIBACTERIUM ACNES; RETINOIDS; SEBUM; SKIN;

EID: 84971590294     PISSN: 21691401     EISSN: 2169141X     Source Type: Journal    
DOI: 10.3109/21691401.2014.916715     Document Type: Review

References (47)

1. An JS, Kim JE, Lee DH, Kim BY, Cho S, Kwon IH, et al. 2011. 0.5% Liposome-encapsulated 5-aminolevulinic acid (ALA) photodynamic therapy for acne treatment. J Cosmet Laser Ther. 13: 28-32.
2. Bettoli V, Sarno O, Zauli S, Borghi A, Minghetti S, Ricci M, et al. 2010. [What's new in acne? New therapeutic approaches]. Ann Dermatol Venereol. 137 Suppl 2:S81-S85.
3. Borges VR, Simon A, Sena AR, Cabral LM, de Sousa VP 2013. Nano-emulsion containing dapsone for topical administration: a study of in vitro release and epidermal permeation. Int J Nanomedicine. 8: 535-544.
4. Brown EJ 1977. A povidone-iodine skin cleanser foam in the management of acne vulgaris. Br J Clin Pract. 31: 218-219.
5. Castro GA, Ferreira LA. 2008. Novel vesicular and particulate drug delivery systems for topical treatment of acne. Expert Opin Drug Deliv. 5: 665-679.
6. Castro GA, Oliveira CA, Mahecha GA, Ferreira LA. 2011. Comedolytic effect and reduced skin irritation of a new formulation of all-trans retinoic acid-loaded solid lipid nanoparticles for topical treatment of acne. Arch Dermatol Res. 303: 513-520.
7. Castro GA, Orefice RL, Vilela JM, Andrade MS, Ferreira LA. 2007. Development of a new solid lipid nanoparticle formulation containing retinoic acid for topical treatment of acne. J Microencapsul. 24: 395-407.
8. Del Rosso JQ. 2009. The use of sodium sulfacetamide 10%-sulfur 5% emollient foam in the treatment of acne vulgaris. J Clin Aesthet Dermatol. 2: 26-29.
9. Dominguez-Delgado CL, Rodriguez-Cruz IM, Escobar-Chavez JJ, Calderon-Lojero IO, Quintanar-Guerrero D, Ganem A. 2011. Preparation and characterization of triclosan nanoparticles intended to be used for the treatment of acne. Eur J Pharm Biopharm. 79: 102-107.
10. Eichenfield LF, Hebert AA, Schachner L, Paller AS, Rossi AB, Lucky AW. 2012. Tretinoin microsphere gel 0.04% pump for treating acne vulgaris in preadolescents: a randomized, controlled study. Pediatr Dermatol. 29: 598-604.
11. Fireman S, Toledano O, Neimann K, Loboda N, Dayan N. 2011. A look at emerging delivery systems for topical drug products. Dermatol Ther. 24: 477-488.
12. Fluhr JW, Barsom O, Gehring W, Gloor M. 1999. Antibacterial efficacy of benzoyl peroxide in phospholipid liposomes. A vehicle-controlled, comparative study in patients with papulopustular acne. Dermatology. 198: 273-277.
13. Fu LW, Vender RB. 2011. Newer approaches in topical combination therapy for acne. Skin Therapy Lett. 16: 3-6.
14. Garg T, Singh O, Arora S, Murthy R. 2012. Scaffold: a novel carrier for cell and drug delivery. Crit Rev Ther Drug Carrier Syst. 29: 1-63.
15. Garg T, Singh S, Goyal AK. 2013. Stimuli-sensitive hydrogels: an excellent carrier for drug and cell delivery. Crit Rev Ther Drug Carrier Syst. 30: 369-409.
16. Honzak L, Sentjurc M. 2000. Development of liposome encapsulated clindamycin for treatment of acne vulgaris. Pflugers Arch. 440: R44-R45.
17. Inui S, Aoshima H, Ito M, Kobuko K, Itami S. 2012. Inhibition of sebum production and Propionibacterium acnes lipase activity by fullerenol, a novel polyhydroxylated fullerene: potential as a therapeutic reagent for acne. J Cosmet Sci. 63: 259-265.
18. Inui S, Aoshima H, Nishiyama A, Itami S. 2011. Improvement of acne vulgaris by topical fullerene application: unique impact on skin care. Nanomedicine. 7: 238-241.
19. Jelvehgari M, Siahi-Shadbad MR, Azarmi S, Martin GP, Nokhodchi A. 2006. The microsponge delivery system of benzoyl peroxide: preparation, characterization and release studies. Int J Pharm. 308: 124-132.
20. Kaur N, Puri R, Jain SK. 2010. Drug-cyclodextrin-vesicles dual carrier approach for skin targeting of anti-acne agent. AAPS PharmSciTech. 11: 528-537.
21. Kim W, Mancini AJ. 2013. Acne in childhood: an update. Pediatr Ann. 42: 418-427.
22. Kircik LH 2011. Microsphere technology: hype or help? J Clin Aesthet Dermatol. 4: 27-31.
23. Kumar A, Agarwal SP, Ahuja A, Ali J, Choudhry R, Baboota S. 2011. Preparation, characterization, and in vitro antimicrobial assessment of nanocarrier based formulation of nadifloxacin for acne treatment. Pharmazie. 66: 111-114.
24. Leyden JJ, Tanghetti EA, Miller B, Ung M, Berson D, Lee J. 2002. Once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.1% micro-sponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial. Cutis. 69: 12-19.
25. Leyden J, Wortzman M, Baldwin EK. 2009. Tolerability of clindamycin/tretinoin gel vs. tretinoin microsphere gel and adapalene gel. J Drugs Dermatol. 8: 383-388.
26. Lin CH, Fang YP, Al-Suwayeh SA, Yang SY, Fang JY. 2013. Percutaneous absorption and antibacterial activities of lipid nanocarriers loaded with dual drugs for acne treatment. Biol Pharm Bull. 36: 276-286.
27. Liu CH, Huang HY. 2012. Antimicrobial activity of curcumin-loaded myristic acid microemulsions against Staphylococcus epidermidis. Chem Pharm Bull (Tokyo). 60: 1118-1124.
28. Liu CH, Huang HY. 2013. In vitro anti-propionibacterium activity by curcumin containing vesicle system. Chem Pharm Bull (Tokyo). 61: 419-425.
29. Lolis MS, Bowe WP, Shalita AR. 2009. Acne and systemic disease. Med Clin North Am. 93: 1161-1181.
30. Lucky AW, Sugarman J. 2011. Comparison of micronized tretinoin gel 0.05% and tretinoin gel microsphere 0.1% in young adolescents with acne: a post hoc analysis of efficacy and tolerability data. Cutis. 87: 305-310.
31. Parnami N, Garg T, Rath G, Goyal AK. 2013. Development and characterization of nanocarriers for topical treatment of psoriasis by using combination therapy. Artif Cells Nanomed Biotechnol. (Epub ahead of print).
32. Patwardhan SV, Kaczvinsky JR, Joa JF, Canfield D. 2013. Auto-classification of acne lesions using multimodal imaging. J Drugs Dermatol. 12: 746-756.
33. Pauli SL, Reunala T. 1987. [Acne fulminans - a systemic disease refractory to treatment]. Duodecim. 103: 835-839.
34. Pornpattananangkul D, Fu V, Thamphiwatana S, Zhang L, Chen M, Vecchio J, et al. 2013. In vivo treatment of Propionibacterium acnes infection with liposomal lauric acids. Adv Healthc Mater. 2: 1322-1328.
35. Prasad S, Mukhopadhyay A, Kubavat A, Kelkar A, Modi A, Swarnkar B, et al. 2012. Efficacy and safety of a nano-emulsion gel formulation of adapalene 0.1% and clindamycin 1% combination in acne vulgaris: a randomized, open label, active-controlled, multi-centric, phase IV clinical trial. Indian J Dermatol Venereol Leprol. 78: 459-467.
36. Raza K, Singh B, Singal P, Wadhwa S, Katare OP. 2013. Systematically optimized biocompatible isotretinoin-loaded solid lipid nanoparticles (SLNs) for topical treatment of acne. Colloids Surf B Biointerfaces. 105: 67-74.
37. Ridolfi DM, Marcato PD, Justo GZ, Cordi L, Machado D, Duran N. 2012. Chitosan-solid lipid nanoparticles as carriers for topical delivery of tretinoin. Colloids Surf B Biointerfaces. 93: 36-40.
38. Rolland A, Wagner N, Chatelus A, Shroot B, Schaefer H. 1993. Site-specific drug delivery to pilosebaceous structures using polymeric microspheres. Pharm Res. 10: 1738-1744.
39. Schafer-Korting M, Korting HC, Ponce-Poschl E. 1994. Liposomal tretinoin for uncomplicated acne vulgaris. Clin Investig. 72: 1086-1091.
40. Shah KA, Joshi MD, Patravale VB. 2009. Biocompatible micro-emulsions for fabrication of glyceryl monostearate solid lipid nanoparticles (SLN) of tretinoin. J Biomed Nanotechnol. 5: 396-400.
41. Simonart T. 2012. Newer approaches to the treatment of acne vulgaris. Am J Clin Dermatol. 13: 357-364.
42. Tanghetti EA 2013. The role of inflammation in the pathology of acne. J Clin Aesthet Dermatol. 6: 27-35.
43. Vender R. 2012. Double-blinded, vehicle-controlled proof of concept study to investigate the recurrence of inflammatory and noninflammatory acne lesions using tretinoin gel (microsphere) 0.04% in male patients after oral isotretinoin use. Dermatol Res Pract. 2012: 736532.
44. Viyoch J, Pisutthanan N, Faikreua A, Nupangta K, Wangtorpol K, Ngokkuen J. 2006. Evaluation of in vitro antimicrobial activity of Thai basil oils and their micro-emulsion formulas against Propionibacterium acnes. Int J Cosmet Sci. 28: 125-133.
45. Well D. 2013. Acne vulgaris: a review of causes and treatment options. Nurse Pract. 38: 22-31.
46. Williams HC, Dellavalle RP, Garner S. 2012. Acne vulgaris. Lancet. 379: 361-372.
47. Yeung CK, Shek SY, Yu CS, Kono T, Chan HH. 2011. Liposome-encapsulated 0.5% 5-aminolevulinic acid with intense pulsed light for the treatment of inflammatory facial acne: a pilot study. Dermatol Surg. 37: 450-459.